Emergent BioSolutions (EBS) Tops Q1 EPS by 23c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.08 -0.74%
Revenue Growth %: +32.0%
Financial Fact:
Net income (loss) attributable to Emergent BioSolutions Inc.: 21.34M
Today's EPS Names:
CCEL, SLP, TMQ, More
Revenue Growth %: +32.0%
Financial Fact:
Net income (loss) attributable to Emergent BioSolutions Inc.: 21.34M
Today's EPS Names:
CCEL, SLP, TMQ, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q1 EPS of $0.16, $0.23 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $111 million versus the consensus estimate of $101.83 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Bernstein: 'Case studies from Microchip and other Semiconductor LTAs - What's different this time?'
- Goldman lowers Mattel rating to Sell on macro and execution risks; shares dip
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
